Recent comparative research is challenging long-standing marketing narratives about ubiquinol’s superiority as a CoQ10 supplement form. A crossover study examining seven different CoQ10 formulations revealed that crystal-dispersed ubiquinone formulations actually demonstrate twice the bioavailability of ubiquinol soft gels, contradicting claims that the reduced form offers enhanced absorption.
The research underscores a fundamental biological reality: regardless of which CoQ10 form consumers ingest, 95-98% of the compound circulating in blood exists as ubiquinol. This occurs because the human body efficiently converts between ubiquinone and ubiquinol during intestinal absorption and cellular metabolism. Enterocytes naturally reduce ubiquinone to ubiquinol, while ubiquinol oxidizes back during transport.
These findings suggest that manufacturing processes and formulation technology—not molecular form—determine clinical effectiveness. Healthcare providers and patients should focus on product quality and bioavailability data rather than marketing claims emphasizing one molecular form over another.
Read the full article on GMJ Newsroom.
Was this article helpful?
